Hosted on MSN8h
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis PatientsJohnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback